Search

Displaying results 3941 - 3950 of 4334 in total
  1. Drug

    Dovitinib

    go.drugbank.com/drugs/DB05928
    Investigational

    Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with...

  2. Drug

    QS-21

    go.drugbank.com/drugs/DB05400
    Investigational

    As a vaccine additive, it is currently being evaluated in clinical trials in a variety of disease areas by Antigenics.

  3. Drug

    Valinomycin

    go.drugbank.com/drugs/DB14057
    Experimental

    (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies.

  4. Drug

    Zorecimeran

    go.drugbank.com/drugs/DB15843
    Investigational

    As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence Phase 1 clinical trials of this vaccine (NCT04449276).

  5. Drug

    APL-9

    go.drugbank.com/drugs/DB16460
    Investigational

    It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life.

  6. Drug

    3'-phospho-5'-adenylyl sulfate

    go.drugbank.com/drugs/DB02902
    Experimental

    3'-phospho-5'-adenylyl sulfate is a key intermediate in the formation by living cells of sulfate esters of phenols, alcohols, steroids, sulfated polysaccharides, and simple esters, such as choline sulfate

  7. Drug

    Lubiprostone

    go.drugbank.com/drugs/DB01046
    ApprovedInvestigational

    Lubiprostone is a medication used in the management of idiopathic chronic constipation. A prostaglandin E1 derivative, lubiprostone is a bicyclic fatty acid that activates ClC-2 chloride channels located on the apical side of the gastroi...

  8. Drug

    EVT 302

    go.drugbank.com/drugs/DB06057
    Investigational

    EVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.

  9. Drug

    Radotinib

    go.drugbank.com/drugs/DB12323
    Investigational

    Radotinib is under investigation for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

  10. Drug

    BL-1020

    go.drugbank.com/drugs/DB05687
    Investigational

    BL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).